💉Biotech Industry Primer💉

A hot nurse stabs one in ur arm. Wohoo! Ur immune to COVID! (ish)
Now how did this lil vax make it from bench to bedside?
👇
1/ Overview
--Pre-launch
2/ FDA stages
3/ Key drivers
--Post-launch
4/ Supply Chain
5/ Trends
--COVID
6/ Price tag
7/ History
1/ US pharma in a nutshell: high capex, highly regulated, long time to profitability.

Recent industry-wide trends (last 5-10yrs):
- Higher cost to bring drugs to market
- Pricing pressure from shift to value-based care
- Decreasing # of late stage pipeline assets
- Consolidation
Today, pharma co's face 3 main types of risk.

Scientific
- 12 yrs avg time to market
- only 0.1% of drugs make it to human testing from preclinical

Delivery
- KOLs/marketing
- payer resistance
- govt scrutiny

Economic
- declining ROI
- competition via generics
- patent cliffs
Pharma investment specializes into 2 niches (chronologically).

- pre-launch (before drug is sellable) focuses on scientific & clinical analysis
- post-launch (after FDA approval) focuses on commercialization & marketing

Usually, separate analysts cover each niche at a fund.
Pre- vs. post-launch analysis tracks different catalysts & KPIs.

Pre:
- catalysts are bimodal events around FDA approval (e.g. PDUFA)
- target co’s are startups
Post:
- all about drug adoption curves
- catalysts are M&A & earnings
- diverse target co's (e.g. CMOs, distributors)
2/ Pre-launch: FDA Stages

Getting to market is entirely about gaining FDA approval.
There are multiple stages: preclinical --> clinical - phases I, II, III --> final review/approval.

Below is a diagram & description of the drug development funnel:
Preclinical trials: 3+ yrs, testing on lab animals to gather toxicity & efficacy. Must file IND (investigative new drug application) at the end, summarizing preclinical results in order to initiate clinical testing (0.1% get approved).

Clinical trials: 6+ yrs, testing on humans.
NDAs (new drug applications): submitted after successful human clinical trials, reviewed by AC (advisory committee)
- PDUFA date: deadline for FDA to announce decision
- Usually takes 1-2yrs but can be fast-tracked
- ~6m expedited approval on drugs addressing "high unmet need"
3/ Key Catalysts

- clinical trial results (phases I, II, III)
- AC (advisory) vote results
- PDUFA announcement
- regulatory path clarifications
- "orphan-drug" designation (OD status provides exclusivity for rare disease drugs; benefits: extra 7 yrs of patent protection)
A biotech investor who wishes to stay anon describes how to analyze clinical trials:

- Trial design: is it double blind or open-label?
- Control treatment: is it placebo or head-to-head comparison vs currently available drug?
- Patient selection: is it the right population?
- Endpoints (the specific metric being measured btw. control group & test group in the clinical study):
Diff. diseases have diff. endpoints (e.g. AIDS uses amount of HIV in blood). Is the primary endpoint approvable by the FDA? Did they talk to the FDA before starting the trial?
- Statistical significance: Do p-values indicate a high probability that reported endpoint results were not by chance?
- Opinions of KOLs (outside doctors not participating in trial): Is there unmet need? What do they think of the MoA of the drug? If approved, how would they use?
4/ Post-Market Ecosystem

A drug is FINALLY approved after 10yrs! The original researchers have gone bald. Now what?
Time to make money & reap everything sown/lost to R&D.

Unfortunately (fortunately?) now it's a huge political game: many players with many different incentives.
Here is a flow-diagram showing how each dollar flows through the ecosystem as a drug travels from manufacturer to patient:
Let's look at each component in depth:

Manufacturers split into:
- "Big Pharma" (e.g. Pfizer, Eli Lily, Merck): mostly rely on M&A of small biotechs to fill their asset pipelines rather than in-house R&D, often outsource manufacturing to CMOs
- CMOs: 3rd party manufacturers
- Wholesale/Distributors: hyper consolidated, basically tri-opoly (CAH, ABC, MCK); brokers that maintain relationships w/ both manufacturers & retail pharmacies/hospitals
- Revenues driven by service fees & discounts/rebates from manufacturer for prompt payment & bulk purchasing
- Pharmacies: account for 75% of the prescription drug market. (non-retail providers e.g. hospitals, HMOs, clinics, nursing homes, etc. comprise 25%)
Increasingly consolidated niche. Tp 5 pharmacies accounted for >70% of prescription revenues.
- PBMs (pharmacy benefit managers): negotiate discounts & rebates w/ manufacturers on behalf of clients (health plan sponsors)
Also super consolidated (notice a pattern much?): top 3 PBMs manage benefits for 70% of health plans. Also highly "integrated" w/ rest of supply chain.
Now how is each $1 split across & passed around the ecosystem?
Who gets the best bang for the least amount of sweat? Who has the highest margins?
Who wins when healthcare costs skyrocket past sustainability?

Here are 3 hypothetical transactions that dig under the hood:
5/ Industry Trends

1. Personalized medicine getting hotter; big pharma M&A eyes gene therapy
2. Regulations driving value-based pricing (mostly in an effort to lower prices)
3. Cooling of M&A from 2015 days (after death of cross-border tax inversion)
4. SPACs looking to de-spac
6/ And the biggest trend of all: COVID

Don't know how mRNAs work. Ask the brilliant @enhancerleo.
But I can tell u abt the HUGE gap btw what countries are paying for the vax.

Pfizer: UK £15 per jab; Belgium £10.6; Israel £34
Moderna: US $15, EU $18
AZ: UK £1.56; S. Africa: £3.8
For funzies let's toast to more political leadership faux pas besides Trump:
7/ COVID Vax History

It's incredible that in less than 1.5 yrs, we've gone from panic, FUD, & global outbreak to 50% of the US (131M ppl) fully-vaxed.

This timeline from Moderna is not only an educational case study showing the FDA stages but a trophy of medical progress.
Huge shout-out to my real-life friend @black6cap for sharing his insights & notes!! I know nothing. He's the guru! 😀🧠

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Ming Zhao

Ming Zhao Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @FabiusMercurius

28 May
🍿🎥AMC Gamma Squeeze Explained in 3 Pictures🎥🍿

Best time to learn about gamma squeeze was for $GME.
2nd best time to learn is now. For $AMC.

You don't needa understand gamma, vega, vanna, theta. You just gotta understand 3 simple pictures.
👇 Image
1/ You buy 1 call option.

The market maker (MM) wants to stay "delta neutral" (i.e. zero net long, zero net short exposure).
But he just sold you 1 call. So he's short 1 call (i.e. short 100 shares' worth of exposure).

What does he do now? 😳🥴 Image
2/ Don't worry. Market maker has a solution.

In response to being short 100 shares' risk, he needs to buy back 50 shares of underlying $AMC stock to bring himself back to "equilibrium."

Why not 100? Go to step 3 (final) 👉 Image
Read 6 tweets
21 May
📀Semiconductor Industry Primer💿

Semis are 🔥🔥 in 2021! But how to trade ‘em?
Hot take: chips are commodities. Trade like oil, not tech.
👇
1 Ecosystem overview
2 Supply chain
3 Key drivers
4 Key Metrics
5 Macro catalysts
6 What's going on in 2021? COVID run-up & sell-off 📈📉
1/ Ecosystem

Semis trade like oil. Calling them "tech" is just deceiving.
What separates gurus from newbs isn’t knowing about wafers. It’s understanding the global value chain & drivers of supply/demand.

Here's a market map of key players & where they sit in the supply chain.
First, slice the ecosystem:
👉by component type (Memory, Logic, µP, Analog)
👉by end-market (Comms, PC, Consumer, Industrial, Auto)

Then identify top players per component product & per end-market.

Then trace demand flow:
from component type (source) ➡️ each end-market (dest).
Read 16 tweets
18 May
💻Tech Sector Primer: Catalysts, KPIs, Valuation Multiples & Red Flags 💻

The analyst next door won't shut up about the weather. "Cloud. Fog. Lakes. $SNOW!"
Soon it'll be animals. "Hive. Pig. Python!"

Welcome to tech, the most confusing sector w/ the most confused investors.
👇
1/ Subsectors

Tech is a vast umbrella, spanning different business models with different go-to-markets, customers & KPIs.
Creating a good market map is the #1 challenge. Go too broad & everything looks like SaaS; go too deep & your brains'll blow out fast.
Here's how i segment the land:
A. Consumer tech:
- internet/mobile apps
- hardware & IoT
B. Enterprise tech:
- SaaS
- services
- infrastructure (software, data, & IT/network)
- hardware & semis

For each subsector I'll cover its business models, metrics, catalysts & multiples.
Read 24 tweets
14 May
🪞How Hedge Funds Do Post-Mortems🪞

"Pain+Reflection=Progress" ~Ray Dalio
The post-mortem is the hedge fund PM's leg day: can't skip.

Done right, it's a systematic exercise that mega boosts performance. Yet ppl never explain how to do one.
So @SeifelCapital(CS) & I teamed up
👇
0/ Start with "pre-mortem"

Think back to when u entered the trade.
1. What asymmetric risk-reward opportunity did you see? 2. What catalysts would drive results in ur favor?
3. What risks were u wary of?

We'll do a 2nd follow-up🧵to focus on pre-mortem but here's a sneak peak:
1/ PnL Results

Fast-forward back to today. The catalyst you'd been playing for just happened (e.g. earnings, demo day, FOMC)

Your brokerage acct says +8%.
"So my thesis was correct!" you think.
Not quite.
CS explains "Look at both absolute return & risk adjusted return."
Read 15 tweets
13 May
📉Why #Inflation Triggers A Sell-Off?📉

Today's news that CPI surged 4.2% sent equities and crypto markets to hell. But WHY??
What are the mechanics of how inflation affects equities, and why is tech falling hardest?

Here's a thread on inflation's 1st & 2nd order effects.
👇
1/ Inflation Lowers the NPV of Money

Say I'll give u $100 in 1yr. How much 💸is that worth today? If every $1 you invest now can earn 3% interest, then it's worth ~$97.
Let's add hypothetical inflation of 2%. Now the real rate is 5%. So your promised $100 is only $95.
What does lower NPV mean for stock valuations?

If you've done DCFs, you know that the equity value of a company is literally the sum of its cashflows projected out to ♾ then discounted back to today.

Inflation -> higher discount rate -> higher denominator -> lower equity value
Read 14 tweets
10 May
📝How to Make Sense of Earnings Calls📝

You hear about the hottest earnings this week: $UPST, $ABNB, $PLTR, $DIS ... & excitedly tune in to your 1st call.
2min later. "What r they talkin' abt? How does this help me trade??"

So many metrics, which are important?
Here's a guide👇 Image
1/ Pre-call diligence

To know what's going on, u should collect the following info ahead of call:
a. Street estimates on revenue, EBIT, & EPS
b. Latest guidance #'s from mgmt
c. Last 4 quarters' revenue/EPS beats/misses & how the stock reacted
d. Last 4 quarters' QoQ growth #'s
Example:
$DIS reports Q2 '21 results on 5/13
I've pulled actual v. estimated EPS from the last 4 quarters & corresponding stock performance.

Things to note:
- actual EPS consistently beats estimates (which means $DIS mgmt team is conservative about providing forward guidance) Image
Read 13 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(